Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov 27:6:492.
doi: 10.1186/1756-0500-6-492.

Stereotactic Body radiation therapy for liver tumors with or without rotational intensity modulated radiation therapy

Elodie Nouhaud  1 , Gilles Créhange, Adèle Cueff, Magali Quivrin, Magali Rouffiac-Thouant, Laurent Mineur, Robin Garcia, Jérôme Chamois, Philippe Maingon
Affiliations

Stereotactic Body radiation therapy for liver tumors with or without rotational intensity modulated radiation therapy

Elodie Nouhaud et al. BMC Res Notes. .

Abstract

Background: To evaluate the feasibility and efficacy of Stereotactic body radiation therapy (SBRT) for primary liver lesions and liver metastases treated with linear accelerators with or without rotational Intensity Modulated RadioTherapy (IMRT).

Methods: Patients with either hepatocellular carcinoma, cholangiocarcinoma or metastatic liver lesions who had one to three lesions treated with SBRT in a single institution were retrospectively reviewed. Tumor response was evaluated according to EASL criteria 3 months after SBRT completion using MRI and/or abdominal CT scan. Responses were categorised as: Stable Disease (SD), Partial Response (PR), Complete Response (CR), Local Progression or Distant Progression in cases of new intra-hepatic lesions out-of-field or extra-hepatic metastases. Local Control (LC), Progression Free Survival (PFS), Overall Survival (OS) and treatment-related toxicities are reported.

Results: Between 2007 and 2012, 20 patients with a total of 24 lesions were treated with SBRT. Fourteen patients presented hepatocellular carcinoma (HCC), the others had either metastatic lesions from colorectal cancer (CRC) or cholangiocarcinoma. The median diameter of the lesions was 23 mm (5-98).The dose per fraction ranged from 6 to 20 Gy with a median total dose of 60 Gy (range: 36-60 Gy). The dose was prescribed to the 80% isodose line covering the PTV.The median follow-up was 24 months (15.7-29.7).The actuarial LC rate was 78% for patients with HCC and 83% for those with adenocarcinoma and cholangiocarcinoma. Median OS was 37 months and OS rates were 83% at 12 and 24 months for HCC and 100% for adenocarcinoma. PFS was 54% for HCC and 50% for other types of tumors at 24 months.Acute grade 3-4 toxicities occurred in 2 patients; a small proportion of the other patients experienced grade 1 or 2 toxicities.

Conclusions: SBRT provides excellent local control with minimal side effects in selected patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Local control.
Figure 2
Figure 2
Overall survival.
Figure 3
Figure 3
Progression free survival.
See this image and copyright information in PMC

References

    1. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):c447–c453. doi: 10.1016/j.ijrobp.2011.04.011. - DOI - PubMed
    1. Tsai YC, Tsai CL, Hsu FM, Jian-Kuen W, Chien-Jang W, Cheng JC. Superior liver sparing by combined coplanar/noncoplanar volumetric-modulated arctherapy for hepatocellular carcinoma: a planning and feasibility study. Med Phys. 2013;38:366–371. - PubMed
    1. Timmerman RD, Kavanagh BD, Cho LC. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25(8):947–952. doi: 10.1200/JCO.2006.09.7469. - DOI - PubMed
    1. Mac Dermed DM, Weichselbaum RR, Salama JK. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol. 2008;98:202–206. doi: 10.1002/jso.21102. - DOI - PubMed
    1. Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, Mancosu P, Reggiori G, Fogliata A, Torzilli G, Tomatis S, Cozzi L. Is stereotactic body radiation therapy an attractive option for resectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86(2):336–342. doi: 10.1016/j.ijrobp.2012.12.021. - DOI - PubMed